Syros Pharmaceuticals Company Insiders
| SYRS Stock | USD 0.24 0.01 4.00% |
Syros Pharmaceuticals employs about 68 people. The company is managed by 14 executives with a total tenure of roughly 24 years, averaging almost 1.0 years of service per executive, having 4.86 employees per reported executive. Breaking down Syros Pharmaceuticals' management performance can provide insight into the firm performance.
| Christian Fritz President Vice President - Biology |
Syros |
Syros Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.5988) % which means that it has lost $0.5988 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.7696) %, meaning that it created substantial loss on money invested by shareholders. Syros Pharmaceuticals' management efficiency ratios could be used to measure how well Syros Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Syros Pharmaceuticals Workforce Comparison
Syros Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,654. Syros Pharmaceuticals holds roughly 68.0 in number of employees claiming about 2.56% of equities under Health Care industry.
Syros Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Syros Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Syros Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Syros Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Syros Pharmaceuticals Notable Stakeholders
A Syros Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Syros Pharmaceuticals often face trade-offs trying to please all of them. Syros Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Syros Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Conley Chee | President CEO | Profile | |
| Christian Fritz | Vice President - Biology | Profile | |
| Richard Young | Independent Director | Profile | |
| Karen MS | Director Relations | Profile | |
| James MD | Founder | Profile | |
| Lisa Roberts | Vice Resources | Profile | |
| JD Esq | Chief Development | Profile | |
| Eric Olson | Chief Scientific Officer | Profile | |
| Jason Haas | Chief Officer | Profile | |
| Courtney Solberg | Mang Relations | Profile | |
| Kristin Stephens | Chief Officer | Profile | |
| Nancy MD | CEO Pres | Profile | |
| Nathanael Gray | Scientific Board | Profile | |
| David MD | Chief Officer | Profile |
About Syros Pharmaceuticals Management Performance
The success or failure of an entity such as Syros Pharmaceuticals often depends on how effective the management is. Syros Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Syros management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Syros management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Syros Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people.
Please note, the imprecision that can be found in Syros Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Syros Pharmaceuticals. Check Syros Pharmaceuticals' Beneish M Score to see the likelihood of Syros Pharmaceuticals' management manipulating its earnings.
Syros Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Syros Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Syros Pharmaceuticals within its industry.Syros Pharmaceuticals Manpower Efficiency
Return on Syros Pharmaceuticals Manpower
| Revenue Per Employee | 146.1K | |
| Revenue Per Executive | 709.7K | |
| Net Loss Per Employee | 2.4M | |
| Net Loss Per Executive | 11.8M | |
| Working Capital Per Employee | 1.6M | |
| Working Capital Per Executive | 7.7M |
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.